BALTIMORE, MD -- (Marketwired) -- 08/16/13 -- In a newly released research update, Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that On the heels of closing the acquisition of licenses representing the exclusive rights to the live-cell encapsulation platform for pancreatic and other cancers, Nuvilex, Inc. (OTCQB: NVLX) announced via a shareholder update that it is in the process of securing similar rights for diabetes treatment as well. Funding has been committed and the closing is expected no later than the end of October 2013.
Given the alarming statistics and the fact that there is a real unmet need, this is tremendous news for the Company and its shareholders.
Diabetes is a major health issue in the United States and other industrialized nations. According to the American Diabetes Association, nearly 24 million people in the U.S., or 8% of the population, have either Type I or Type II diabetes. Estimates indicate that nearly 25% of people with the disease are unaware that they have it. Type I is commonly diagnosed in children, where the body does not produce insulin. Type II is developed in adults and is the condition where "insulin resistance" develops (cells of the body do not use insulin effectively), and is particularly tied to obesity or bad diet habits. The number of patients diagnosed with Type II diabetes is growing at an alarming rate. According to the CDC, the rates of Type 2 Diabetes in the US have increased from 4.8 per 1,000 in 1995-1997 to 9.1 per 1,000 in 2005-2007, a 90% increase.
This is why the estimated annual sales of diabetes drugs in the U.S. are $22 billion.
Clinicians and physicians have long known about the undefined correlation between the litany of health problems associated with diabetes and the link to pancreatic cancer, which is one of the reasons why the Nuvilex deal makes so much sense.
Clearly, Nuvilex plans to take advantage of the soon-to-be acquired early-stage diabetes treatment technology and research combined with its advanced pancreatic cancer trials data to leverage its platform live-cell encapsulation technology to treat both diseases. Moreover, considering that the animal study data to date indicates that the need for insulin therapy could be eliminated through the use of its live-cell encapsulation-based technology, Nuvilex is moving yet another step closer toward introducing a game-changing multi-disease treatment platform that is potentially worth billions in annual sales.
To view Nuvilex reports and articles or to download the report in its entirety, please visit
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.
Goldman Small Cap Research
Most Popular Stories
- Americans Still Pessimistic Despite Economic Growth
- Obama's Delay on Immigration Creates Uncertainty
- Obama on Labor Day: Don't Take Rights for Granted
- New Hershey's Logo Revealed
- Buyer's Remorse on Common Core for Policymakers?
- California Passes First US Statewide Bag Ban
- Mexico's Pemex Forecasts 6.7% Drop in 2014 Crude Production
- American Airlines Back on Obitz
- Echeveste Steps Down, Perez Steps Up at VPE
- Startups Offer Smartphone Banking Apps